In this study, a combined therapy involving DMR with PD‐1 blockade was conducted in MSS CRC tumor model, and it was found that DMR promotes the infiltration and function of CD8+ T cells and potentiates PD‐1 blockade therapy by decreasing PCSK9 expression. Here, CD8A is linked to neoplasm.